Latest news with #ShyamakantGiri
Business Standard
06-08-2025
- Business
- Business Standard
Gland Pharma gains after Q1 PAT climbs 50% YoY to Rs 215 cr
Gland Pharma advanced 1.36% to Rs 1,991.15 after the company's consolidated net profit surged 49.88% to Rs 215.48 crore in Q1 FY26 as against Rs 143.76 crore posted in Q1 FY25. Revenue from operations increased by 7.41% YoY to Rs 1,505.62 crore for the quarter ended 30 June 2025. Profit before tax (PBT) stood at Rs 312.74 crore in Q1 FY26, up 43.29% from Rs 218.25 crore recorded in Q1 FY25. EBITDA for the quarter came in at Rs 367.8 crore, marking a 38.58% growth YoY. The EBITDA margin improved to 24%, compared to 19% in the same period last year. On the geographical revenue front, Revenue from the US market stood at Rs 744.3 crore (down 2.42% YoY), revenue from Europe was at Rs 330.2 crore (up 28.68% YoY), Canada, Australia, and New Zealand stood at Rs 73.9 crore (up 65.32% YoY), Revenue from India was at Rs 59.4 crore (up 12.71% YoY) and the rest of the world was at Rs 297.8 crore (up 4.52% YoY) during the period under review. Total capex for the quarter rose 23.39% to Rs 78.6 crore in Q1 FY26, compared to Rs 63.7 crore in the same period last year. The companys total R&D expenses were Rs 46 crore in Q1 FY26, representing 4.4% of revenue. During Q1 FY26, the company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (in three new strengths), Liraglutide, and Acetaminophen Bags. Additionally, one ANDA (Abbreviated New Drug Application) was filed and nine were approved in Q1 FY26, contributing to a cumulative total of 372 ANDA filings in the U.S. (325 approved, 47 pending). Srinivas Sadu, Executive Chairman of Gland Pharma, said, We're off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships. We're committed to building on this strong foundation, improving our performance, and reinforcing Gland's path toward sustainable growth Shyamakant Giri, CEO, Gland Pharma, said, This quarters performance, with improved margins and Cenexi achieving EBITDA break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth. At the same time, our continued focus on R&D, adherence to global quality standards, and investment in capability building position us to scale further, tap new markets, and deliver long-term value. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.
&w=3840&q=100)
Business Standard
06-08-2025
- Business
- Business Standard
Gland Pharma shares jump 6% post Q1 show; should you buy, sell or hold?
Gland Pharma share price today: Shares of pharmaceutical company, Gland Pharma, jumped over 6 per cent on Wednesday, August 6, 2025, hitting an intraday high of ₹2,089.40. At 9:35 AM, Gland Pharma shares were trading at ₹2,004.1, up over 2 per cent on the National Stock Exchange. In comparison, Nifty50 was trading largely flat, albeit with a negative bias, quoting 24,631.90 level, down by 17 points or 0.07 per cent. The shares of the company were trading just 6 per cent lower when compared to 52-week high of ₹2,220. The total market capitalisation of the company stood at ₹32,974.35 crore. The buying interest on the counter came after the company released its earnings for the first quarter of the financial year 2025-2026 (Q1FY26). Gland Pharma Q1FY26 earnings The pharma company's profit after tax (PAT) for the quarter ended June 30, 2025, stood at ₹215 crore, up 50 per cent from ₹143 crore reported in the corresponding quarter of the previous fiscal year. Consolidated revenue from operations figures stood at ₹1,505 crore in Q1FY26, as against ₹1,401 crore reported in the year-ago period, marking a rise of 7 per cent. Earnings before interest, taxes, depreciation and amortisation (Ebitda) figure advanced 39 per cent to ₹367 crore during the quarter under review as compared to ₹265 crore reported in the first quarter of the last fiscal year. PAT margins stood at 14 per cent in Q1FY26. The figure stood at 10 per cent in the year-ago period. That apart, the company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen Bags. 'This quarter's performance, with improved margins and Cenexi achieving Ebitda break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth," said Shyamakant Giri, chief executive officer of Gland Pharma. What should investors do? The pharma company reported a strong double-digit rise in earnings after four quarters of consecutive decline. While the company's core market sales remained moderate, analysts at Motilal Oswal Financial Services believe that new launches will improve the outlook for the coming quarters. The brokerage firm has maintained a 'Buy' rating on the stock with a target price (TP) of ₹2,340. "After three years of earnings decline, we expect a compound annual growth rate (CAGR) of 14 per cent/20 per cent/27 per cent in revenue/Ebitda/Pat over FY25-27. Gland is fortifying its positioning in the complex injectable space through in-house product development as well as partnerships. It is in the process of adding capacity to cater to upcoming GLP-1 opportunities as well. Considering 1Q earnings growth and valuation, we maintain 'BUY' on the stock," the brokerage firm said. However, Ravi Singh, SVP-retail research at Religare Broking, has called for a cautious stance, saying that existing investors should wait for an extended price action. "On the weekly chart, the stock has strong resistance around ₹2,220 level, which can act as selling pressure and buyers may get trapped, so traders should cautiously watch the price action near this level. Overall, for now sentiments remain on the sideways to positive side with levels to be focused, existing investors can trail their positions to cost or book some profit near the immediate resistance of ₹2,120 and fresh positions can be recommended once it sustains above ₹2,120-₹2,150 level," said Ravi Singh.
&w=3840&q=100)
Business Standard
05-08-2025
- Business
- Business Standard
Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ₹215 crore for the first quarter of the financial year (Q1FY26). Revenue from operations rose 7 per cent Y-o-Y to ₹1,505 crore. The growth was driven by robust performance in its core business and a successful turnaround at Cenexi, a French pharmaceutical contract development and manufacturing organisation (CDMO) specialising in sterile injectable and lyophilised drug products, which Gland Pharma acquired in 2023. Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent. 'We're off to a positive start this year with growth in revenue and a jump in profitability. Our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships,' said Srinivas Sadu, executive chairman, Gland Pharma. 'By enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth. Our focus on adherence to global quality standards and investment in capability building position us to scale further, tap new markets and deliver long-term value,' said Shyamakant Giri, chief executive officer, Gland Pharma. During the quarter, research and development (R&D) expenses stood at ₹46 crore, accounting for 4.4 per cent of revenue. The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen bags. One abbreviated new drug application (ANDA) was filed and nine were approved during the quarter, bringing cumulative US ANDA filings to 372 (325 approved and 47 pending). Its in-house complex pipeline saw six product launches, with three more awaiting approval. Complex injectables remain a key driver of long-term growth, with more products being added to the pipeline. Fifteen products are in co-development (seven under the 505(b)(2) pathway and eight ANDAs), with commercialisation expected to begin in FY28. One ready-to-use (RTU) infusion bag was filed this quarter, bringing the total RTU product filings in the US to 20 (14 approved). Another 10 are in development, targeting a $767 million market. The company expanded its GLP-1 portfolio, launching Liraglutide in the UK and Australia, and is increasing GLP-1/pen/cartridge capacity from 40 million to 140 million units. It also received a good manufacturing practice (GMP) compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion and inhalation. The results were announced after market hours. Gland Pharma's stock fell by 0.95 per cent, ending the day's trade at ₹1,962.30 per share on the BSE.
The Hindu
05-08-2025
- Business
- The Hindu
Gland Pharma Q1 net surges 50% to ₹216 crore
Gland Pharma reported consolidated net profit rose nearly 50% for the June quarter to ₹215.5 crore from the ₹143.8 crore a year earlier as revenue from all but the key U.S. market increased. The higher net profit came on a more than 7% increase in the revenue from operations to ₹1,505.6 crore (₹1,401.7 crore). Market wise performance numbers showed the Hyderabad-based generic injectable-focused company's revenue from the U.S. declined 2% to ₹744.3 crore (₹762.8 crore). Sales to Canada, Australia and New Zealand (Other Core Markets) increased 65% to ₹73.9 crore (₹44.7 crore), while revenue from Europe went up 29% ₹330.2 crore (₹256.6 crore). In India, sales rose 13% to ₹59.4 crore (₹52.7 crore). Revenue from the Rest of World market increased 5% to ₹297.8 crore (₹284.9 crore). A strong performance in the company's base business and a turnaround at Cenexi, the French firm that Gland acquired a few years ago, were behind the revenue growth and jump in profitability, Executive Chairman Srinivas Sadu said. 'These results show our strategic priorities are progressing. We are strengthening our capabilities, adding new capacity and boosting research and development with complex products and key partnerships,' he said in a release. CEO Shyamakant Giri said, 'by enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth.'
Mint
20-05-2025
- Business
- Mint
Gland Pharma Q4 results: Profit dips 3% YoY to ₹187 crore; 1800% dividend announced
Gland Pharma Q4 Results: Pharma company Gland Pharma on Tuesday, May 20, posted a weak set of numbers for the fourth quarter of the financial year 2024-25 (Q4 FY25), recording a single-digit fall in the consolidated revenue and profit after tax (PAT). Gland Pharma's PAT came in at ₹ 187 crore for the quarter under review, as against ₹ 192 crore in the year-ago quarter, recording a 3% decline on a year-on-year basis. Meanwhile, the revenue from operations declined by 7% YoY to ₹ 1,425 crore in Q4 FY25, from ₹ 1,538 crore in Q4 FY24. On the operating front, the earnings before interest, tax, depreciation and amortisation (EBITDA) also fell 3% YoY to ₹ 348 crore from ₹ 359 crore. The EBITDA margin saw a small uptick to 24% in the March 2024 quarter from 23% in the year-ago period. On a sequential basis, Gland Pharma's revenue rose 3% while PAT was higher by 9%. Shyamakant Giri, Chief Executive Officer of Gland Pharma, commenting on the results, said, 'In Q4 FY25, our consolidated revenue reached INR 14,249 million, with a healthy EBITDA margin of 24%. On the base business, the EBITDA margin expanded to 38%, driven by volume traction in our U.S. portfolio and high-margin new product launches. Cenexi posted modest sequential improvement in revenue and gross margin, and we remain firmly committed to its turnaround.' Going ahead, Giri said the strategic focus would be on accelerating growth in RoW and India, deepening U.S. presence through portfolio enhancement, and continuing to lead on quality and cost efficiency. During the quarter, the company spent ₹ 50.3 crore on research and development (R&D), representing 4.9% of revenue, while for FY25, it was ₹ 1,922 million (4.7% of revenue). In Q4 FY25, Gland Pharma filed five ANDAs and seven got approved, with a total of 24 ANDAs filed and 32 ANDAs approved in FY25, contributing to a cumulative total of 371 ANDA filings in the U.S. (318 approved, 53 pending). Gland Pharma also recommended a final dividend of ₹ 18 or 1800% per equity share of ₹ 1/- each for the financial year 2024-25. The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the 47th Annual General Meeting (AGM), the company said. Furthermore, Gland Pharma also announced the dividend record date. "The record date for the purpose of determining the members eligible to receive the final dividend for the financial year ended March 31, 2025, is Thursday, August 14, 2025," it said.
